Rifaximin anti‐inflammatory activity on bovine endometrium primary cell cultures: a preliminary study

Rifaximin anti‐inflammatory activity on bovine endometrium primary cell cultures: a preliminary study

Abstract Rifaximin is an unabsorbed oral antibiotic showing anti‐inflammatory properties in human pathologies like irritable bowel syndrome and inflammatory bowel disease. In veterinary medicine, rifaximin is primarily used in the treatment of dermatological diseases in all animal species, in therap...

Full description

Bibliographic Details
Main Authors:	Lisa Flammini, Leonardo Mantelli, Alessandra Volpe, Giuseppe Domenichini, Rosanna Di Lecce, Maurizio Dondi, Anna Maria Cantoni, Elisabetta Barocelli, Fausto Quintavalla
Format:	Article
Language:	English
Published:	Wiley 2018-11-01
Series:	Veterinary Medicine and Science
Subjects:	Bovine cell cultures endometrium inflammation rifaximin
Online Access:	https://doi.org/10.1002/vms3.115

Similar Items

Use of Rifaximin in Irritable Bowel Syndrome Treatment
by: Hubert Wróblewski, et al.
Published: (2021-08-01)

Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin
by: Ana L. Sousa, et al.
Published: (2019-08-01)

Impact of crystal polymorphism of rifaximin on dissolution behavior
by: Imen Toukabri, et al.
Published: (2024-03-01)

Steroidal but not embryonic regulation of mucin 1 expression in bovine endometrium
by: Kaiyu KUBOTA, et al.
Published: (2021-10-01)

Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating
by: Kichul Yoon, et al.
Published: (2018-09-01)

Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice
by: Shengyan Zhang, et al.
Published: (2023-01-01)

Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome
by: Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer
Published: (2021-12-01)

Highly Polymorphic Materials and Dissolution Behaviour: The Peculiar Case of Rifaximin
by: Annalisa Bianchera, et al.
Published: (2022-12-01)

EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
by: Hafsa Habib, et al.
Published: (2016-12-01)

Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial
by: Sabine Becker, et al.
Published: (2024-01-01)

Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model
by: Seung Kak Shin, et al.
Published: (2017-11-01)

The effects of rebamipide, sucralfate, and rifaximin against inflammation and apoptosis in radiation-induced murine intestinal injury
by: Won Moon, et al.
Published: (2022-12-01)

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
by: Kosuke Kaji, et al.
Published: (2020-03-01)

Advances in Therapy for Irritable Bowel Syndrome with Diarrhea: Role of Rifaximin in Combination with Metronidazole
by: Arif A Faruqui
Published: (2024-01-01)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
by: Wang Z, et al.
Published: (2018-12-01)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
by: Yasuyuki Tamai, et al.
Published: (2021-07-01)

Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study
by: Takao Miwa, et al.
Published: (2022-12-01)

Effect of Progesterone on Expression of Prostaglandin Synthases and Plasminogen Activator in Bovine Endometrium during Estrous Cycle
by: Su-Bin Choi, et al.
Published: (2016-03-01)

Rifaximin plus norfloxacin versus norfloxacin alone in primary prophylaxis of spontaneous bacterial peritonitis in patients with variceal bleeding
by: Ahmed A Ghafar, et al.
Published: (2019-01-01)

Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies
by: Chien-Tai Hong, et al.
Published: (2022-11-01)

Determination of rifaximine in milk of dairy cows using High Pressure Liquid Chromatography (HPLC)
by: José Luis íngeles Manjarrez, et al.
Published: (2012-04-01)

Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases
by: E. Yu. Plotnikova
Published: (2021-05-01)

Managing Hepatic Encephalopathy - Combination of Lactulose and Rifaximin Versus Lactulose Monotherapy: A meta-analysis
by: Saad Khalid, et al.
Published: (2024-04-01)

Diverticular Disease and Rifaximin: An Evidence-Based Review
by: Anna Piccin, et al.
Published: (2023-02-01)

Rifaximin modulates TRH and TRH-like peptide expression throughout the brain and peripheral tissues of male rats
by: Albert Eugene Pekary, et al.
Published: (2022-02-01)

Monoclonal antibody production and the development of a quantitative time-resolved fluoroimmunoassay for rifaximin in milk
by: Licai Ma, et al.
Published: (2019-01-01)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
by: Alba Mangas-Losada, et al.
Published: (2019-08-01)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
by: Soldi S, et al.
Published: (2015-12-01)

Rifaximin for Pertuzumab-Related GI Toxicities
by: Aixa E. Soyano, et al.
Published: (2017-08-01)

Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy
by: Simona Parisse, et al.
Published: (2023-10-01)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
by: Torre A, et al.
Published: (2023-10-01)

Cyclic rifaximin and soluble dietary fiber therapy for symptomatic diverticular disease: effective prevention of complications
by: E. V. Golovanova
Published: (2019-05-01)

Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis
by: Asmaa N Mohammad, et al.
Published: (2018-01-01)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
by: Xiao Yu, et al.
Published: (2022-01-01)

Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
by: Hideto Kawaratani, et al.
Published: (2022-03-01)

Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy
by: Xianghui Han, et al.
Published: (2021-10-01)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
by: Ming-Wei Wang, et al.
Published: (2023-03-01)

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
by: Yukihisa Fujinaga, et al.
Published: (2020-08-01)

Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review – Are They Potential Eradication Regimens?
by: Wang Y, et al.
Published: (2022-07-01)

Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites
by: Mei Luo, et al.
Published: (2023-10-01)